# IBS-D (Lotronex, Viberzi, Xifaxan) Prior Authorization with Quantity Limit Program Summary

This program applies to FlexRx Closed, FlexRx Open, FocusRx, GenRx Closed, GenRx Open, Health Insurance Marketplace, and KeyRx formularies.

This is a FlexRx Standard and GenRx Standard program.

The BCBS MN Step Therapy Supplement also applies to this program for all Commercial/HIM lines of business.

## POLICY REVIEW CYCLE

| Effective Date | Date of Origin |
|---|---|
| 10-01-2024 | 10-01-2024 |

## FDA LABELED INDICATIONS AND DOSAGE

| Agent(s) | FDA Indication(s) | Notes | Ref# |
|---|---|---|---|
| Lotronex®<br><br>(alosetron)<br><br>Tablet* | For women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have:<br>• chronic IBS symptoms (generally lasting 6 months or longer)<br>• had anatomic or biochemical abnormalities of the gastrointestinal tract excluded and<br>• not responded adequately to conventional therapy.<br><br>Severe IBS includes diarrhea and 1 or more of the following:<br>• frequent and severe abdominal pain/discomfort<br>• frequent bowel urgency or fecal incontinence<br>• disability or restriction of daily activities due to IBS | *generic available | 5 |
| Viberzi®<br><br>(eluxadoline)<br><br>Tablet | Treatment of irritable bowel syndrome with diarrhea in adults | | 1 |
| Xifaxan®<br><br>(rifaximin)<br><br>Tablet | Treatment of travelers' diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older<br><br>Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults<br><br>Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults<br><br>Limitations of Use: TD - Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli | | 2 |

*See package insert for FDA prescribing information: https://dailymed.nlm.nih.gov/dailymed/index.cfm*


© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved

## CLINICAL RATIONALE

<table>
<tr><td>Guidelines</td><td>
Irritable Bowel Syndrome (IBS) is defined as recurrent abdominal pain, on average, at least 1 day/week in the past 3 months, associated with two or more of the following:(3,4,6)
<ul>
<li>Related to defecation</li>
<li>Associated with a change in stool frequency</li>
<li>Associated with a change in stool form (appearance)</li>
</ul>
These criteria should be fulfilled for the past 3 months with symptom onset at least 6 months before diagnosis.(7) IBS is subtyped according to predominant bowel habit as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), and unclassified (IBS-U).(3)
The American College of Gastroenterology (ACG) and the American Gastroenterological Association lists the following in the management of IBS-D:(4,8)
<table>
<tr><th>Intervention</th><th>ACG Recommendation and Strength of Evidence</th><th>AGA Recommendation and Strength of Evidence</th></tr>
<tr><td>Probiotics</td><td>Conditional, very low</td><td>NA</td></tr>
<tr><td>rifaximin (Xifaxan)</td><td>Strong, moderate</td><td>Conditional, moderate</td></tr>
<tr><td>eluxadoline (Viberzi)</td><td>Conditional, moderate</td><td>Conditional, moderate</td></tr>
<tr><td>alosetron (Lotronex)</td><td>Conditional, low</td><td>Conditional, moderate</td></tr>
<tr><td>Tricyclic Antidepressants (TCAs)</td><td>Strong, Moderate</td><td>Conditional, low</td></tr>
<tr><td>Bile acid sequestrants</td><td>Conditional, very low</td><td>NA</td></tr>
<tr><td>antispasmodics</td><td>Conditional, low</td><td>Conditional, low</td></tr>
<tr><td>loperamide</td><td>NA</td><td>Conditional, very low</td></tr>
<tr><td>Selective Serotonin Reuptake Inhibitors (SSRIs)</td><td>NA</td><td>Conditional, low</td></tr>
</table>
Updated ACG guidelines published in 2021, include a strong recommendation for the use of TCAs in the management of IBS-D. Although the 2021 guidelines do not address loperamide use, they do briefly discuss that loperamide is not recommended as first-line therapy for treating IBS-D symptoms because it may improve diarrhea but not improve global IBS symptoms. A recent AGA guideline on probiotics highlighted the evidence gaps in the use of probiotics in patients with IBS and concluded that future, larger, and high-quality studies are needed. In addition, studies evaluating the synergistic effects of combined treatment in IBS, which is often used in patients with moderate to severe symptoms in clinical practice, and better comparative effectiveness studies in IBS are needed. (4,8)
</td></tr>
<tr><td>Safety</td><td>
Alosetron was reintroduced under a risk evaluation and mitigation strategy (REMS) in June 2002, limiting use to women experiencing chronic (greater than 6 months), severe IBS-D symptoms who previously lacked response to traditional therapies. The term “traditional therapies” (or conventional therapies) has not been further defined, and multiple agents have been US FDA-approved for IBS-D in the years since the REMS protocol was established.(4)
Alosetron also carries the following black box warnings:(5)
<ul>
<li>Infrequent but serious gastrointestinal adverse reactions have been reported with the use of alosetron. These events, including ischemic colitis and serious complications of constipation, have resulted in hospitalization and, rarely, blood transfusion, surgery, and death</li>
</ul>
</td></tr>
</table>


© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved

| | |
|---|---|
| | • Alosetron is indicated only for women with severe diarrhea predominant irritable bowel syndrome (IBS) who have not responded adequately to conventional therapy<br>• Discontinue alosetron immediately in patients who develop constipation or symptoms of ischemic colitis. Do not resume alosetron in patients who develop ischemic colitis<br><br>Alosetron carries the following contraindications:(5)<br><br>• Do not initiate in patients with constipation<br>• History of chronic or severe constipation or sequelae from constipation; intestinal obstruction, stricture, toxic megacolon, gastrointestinal perforation, and/or adhesions; ischemic colitis; impaired intestinal circulation, thrombophlebitis, or hypercoagulable state; Crohn's disease or ulcerative colitis; diverticulitis; severe hepatic impairment<br>• Concomitant use of fluvoxamine<br><br>Eluxadoline carries the following contraindications:(1)<br><br>• Patients without a gallbladder<br>• Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction<br>• Alcoholism, alcohol abuse, alcohol addiction, or drink more than 3 alcoholic beverages/day<br>• History of pancreatitis; structural diseases of the pancreas, including known or suspected pancreatic duct obstruction<br>• Patients with a known hypersensitivity reaction to eluxadoline<br>• Severe hepatic impairment (Child-Pugh Class C)<br>• History of chronic or severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction<br><br>Rifaximin carries the following contraindications:(2)<br><br>• History of hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components of rifaximin |

## REFERENCES


| Number | Reference |
|---|---|
| 1 | Viberzi prescribing information. Allergan USA, Inc. June 2020. |
| 2 | Xifaxan prescribing information. Salix Pharmaceuticals, Inc. October 2023. |
| 3 | Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology. 2006; 130:1480–91. |
| 4 | Lacy, Brian E, Pimentel, March, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. The American Journal of Gastroenterology. 2021. 116: 17-44. Available at: https://journals.lww.com/ajg/Fulltext/2021/01000/ACG_Clinical _Guideline_Management_of_Irritable.11.aspx. |
| 5 | Lotronex prescribing information. Sebela Pharmaceuticals, Inc. April 2019. |
| 6 | Reference no longer used. |
| 7 | Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016 Feb. |
| 8 | Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022;163(1):137-151. doi:https://doi.org/10.1053/j.gastro.2022.04.017. |




© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved

## POLICY AGENT SUMMARY PRIOR AUTHORIZATION

| Target Brand Agent(s) | Target Generic Agent(s) | Strength | Targeted MSC | Available MSC | Final Age Limit | Preferred Status |
|---|---|---|---|---|---|---|
| | | | | | | |
| | alosetron hcl tab | 0.5 MG ; 1 MG | Y | O ; Y | | |

## POLICY AGENT SUMMARY QUANTITY LIMIT

| Target Brand Agent Name(s) | Target Generic Agent Name(s) | Strength | QL Amount | Dose Form | Day Supply | Duration | Addtl QL Info | Allowed Exceptions | Targeted NDCs When Exclusions Exist |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | |
| Lotronex | Alosetron HCl Tab 0.5 MG (Base Equiv) | 0.5 MG | 60 | Tablets | 30 | DAYS | | | |
| Lotronex | Alosetron HCl Tab 1 MG (Base Equiv) | 1 MG | 60 | Tablets | 30 | DAYS | | | |

## CLIENT SUMMARY – PRIOR AUTHORIZATION

| Target Brand Agent Name(s) | Target Generic Agent Name(s) | Strength | Client Formulary |
|---|---|---|---|
| | alosetron hcl tab | 0.5 MG ; 1 MG | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Lotronex | alosetron hcl tab | 0.5 MG ; 1 MG | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |

## CLIENT SUMMARY – QUANTITY LIMITS

| Target Brand Agent Name(s) | Target Generic Agent Name(s) | Strength | Client Formulary |
|---|---|---|---|
| Lotronex | Alosetron HCl Tab 0.5 MG (Base Equiv) | 0.5 MG | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |
| Lotronex | Alosetron HCl Tab 1 MG (Base Equiv) | 1 MG | FlexRx Closed ; FlexRx Open ; FocusRx ; GenRx Closed ; GenRx Open ; Health Insurance Marketplace/BasicRx ; KeyRx |

## PRIOR AUTHORIZATION CLINICAL CRITERIA FOR APPROVAL

| Module | Clinical Criteria for Approval |
|---|---|
| Alosetron | **Initial Evaluation** |


© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved

| Module | Clinical Criteria for Approval |
|---|---|
| | **Target Agent(s)** will be approved when ALL of the following are met:<br><br>1. ONE of the following:<br>  A. ALL of the following:<br>    1. The patient has a diagnosis of irritable bowel syndrome with severe diarrhea (IBS-D) **AND**<br>    2. The patient has an onset of IBS-D symptoms starting at least 6 months prior **AND**<br>    3. The patient exhibits at least ONE of the following:<br>      A. Frequent and severe abdominal pain/discomfort **OR**<br>      B. Frequent bowel urgency or fecal incontinence **OR**<br>      C. Disability or restriction of daily activities due to IBS **AND**<br>    4. The patient will NOT be using the requested agent in combination with another agent from this program for IBS-D **AND**<br>    5. ONE of the following:<br>      A. The patient’s sex is female **OR**<br>      B. The requested agent is medically appropriate for the patient’s sex **AND**<br>    6. The patient has had anatomic or biochemical abnormalities of the gastrointestinal tract excluded **AND**<br>    7. ONE of the following:<br>      A. The patient has tried and had an inadequate response to at least ONE conventional therapy **OR**<br>      B. The patient has an intolerance or hypersensitivity to ONE conventional therapy **OR**<br>      C. The patient has an FDA labeled contraindication to ALL conventional therapies **OR**<br>      D. The patient is currently being treated with the requested agent as indicated by ALL of the following:<br>        1. A statement by the prescriber that the patient is currently taking the requested agent **AND**<br>        2. A statement by the prescriber that the patient is currently receiving a positive therapeutic outcome on requested agent **AND**<br>        3. The prescriber states that a change in therapy is expected to be ineffective or cause harm **OR**<br>      E. The prescriber has provided documentation that conventional therapies cannot be used due to a documented medical condition or comorbid condition that is likely to cause an adverse reaction, decrease ability of the patient to achieve or maintain reasonable functional ability in performing daily activities or cause physical or mental harm **OR**<br>  B. The patient has another FDA labeled indication for the requested agent **AND**<br>2. If the patient has an FDA labeled indication, then ONE of the following:<br>  A. The patient’s age is within FDA labeling for the requested indication for the requested agent **OR**<br>  B. There is support for using the requested agent for the patient’s age for the requested indication **AND**<br>3. The patient does NOT have any FDA labeled contraindications to the requested agent<br><br>**Length of Approval:** 3 months<br><br>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria.<br><br>**Renewal Evaluation**<br><br>**Target Agent(s)** will be approved when ALL of the following are met: |


© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved

| Module | Clinical Criteria for Approval |
|---|---|
| | 1. The patient has been previously approved for the requested agent through the plan's Prior Authorization process [Note: patients not previously approved for the requested agent will require initial evaluation review] **AND**<br>2. The patient has had clinical benefit with the requested agent **AND**<br>3. The patient will NOT be using the requested agent in combination with another agent from this program for a diagnosis of IBS-D **AND**<br>4. The patient does NOT have any FDA labeled contraindications to the requested agent<br><br>**Length of Approval:** 12 months<br><br>NOTE: If Quantity Limit applies, please refer to Quantity Limit Criteria. |

## QUANTITY LIMIT CLINICAL CRITERIA FOR APPROVAL

| Module | Clinical Criteria for Approval |
|---|---|
| Universal QL | **Quantity limit for the Target Agent(s)** will be approved when ONE of the following is met:<br><br>1. The requested quantity (dose) does NOT exceed the program quantity limit **OR**<br>2. The requested quantity (dose) exceeds the program quantity limit AND ONE of the following:<br>A. BOTH of the following:<br>1. The requested agent does NOT have a maximum FDA labeled dose for the requested indication **AND**<br>2. There is support for therapy with a higher dose for the requested indication **OR**<br>B. BOTH of the following:<br>1. The requested quantity (dose) does NOT exceed the maximum FDA labeled dose for the requested indication **AND**<br>2. There is support for why the requested quantity (dose) cannot be achieved with a lower quantity of a higher strength that does NOT exceed the program quantity limit **OR**<br>C. BOTH of the following:<br>1. The requested quantity (dose) exceeds the maximum FDA labeled dose for the requested indication **AND**<br>2. There is support for therapy with a higher dose for the requested indication<br><br>**Length of Approval**: up to 12 months |


© Copyright Prime Therapeutics LLC. July 2024 All Rights Reserved